SCIENION AG announced today that it has partnered with RayBiotech, Inc. for the distribution of SCIENION’s sciFLEXARRAYER ultra-low volume dispensing systems and related products in the People’s Republic of China. Under the terms of the agreement, RayBiotech will market and distribute SCIENION’s portfolio of cutting-edge molecular array instrumentation and related software and consumables across China. These include the sciFLEXARRAYER line of non-contact arrayers which have proven to be the industry standard for biochemistry-related high-throughput, arraying applications. The financial terms were not disclosed.
Dortmund and Berlin, Germany; Norcross, Georgia, USA, August 14, 2014:
RayBiotech’s President, Chief Operating Officer and Co-founder, Ms. Rani Huang, stated, “It is with great pleasure that we announce our foray into the arrayer instrumentation business through the execution of this distribution partnership in China. SCIENION is the leading arrayer instrumentation company for automated low volume liquid handling and the company’s equipment and peripherals set an extremely high benchmark in performance and quality. SCIENION’s arrayers and related technologies perfectly complement RayBiotech’s antibody array-basedproduct and services portfolios. We are very enthusiastic about this new product line for RayBiotech and look forward to a successful introduction of these instruments and products across China.”
Also commenting on the agreement, Dr. Holger Eickhoff, Chief Executive Officer of SCIENION AG, stated, “We are delighted to have RayBiotech as our partner organization for the distribution of SCIENION’s sciFLEXARRAYER product line and related products in China, a market of ever increasing importance. Given both, RayBiotech’s longstanding reputation in this region, and its reputation as the leader in the development of antibody- and protein-array based products, it is only fitting to form this partnership. We are looking forward to a successful collaboration with the goal of positioning of our instrumentation in China through RayBiotech’s marketing and distribution efforts.”
About RayBiotech, Inc.
In 2001, RayBiotech (http://www.raybiotech.com) introduced the first commercially available cytokine antibody array. With a focus on translating scientific knowledge into improved health, RayBiotech continues to pioneer advances in high-throughput platforms for identifying disease mechanisms, screening and validation of biomarkers and identification of drug targets. RayBiotech products are manufactured under GMP compliance and ISO 13485:2003 certification and are featured in thousands of publications, including:Nature, Nature Medicine, Science, Cell, Lancet, PNAS and many others. Offering the world’s largest selection of antibody and protein arrays, RayBiotech has established a reputation for high quality and innovation in the research community. A spin-off from Emory University, RayBiotech is privately owned, with headquarters in metro Atlanta (Norcross, GA).
About SCIENION AG
SCIENION AG and its US subsidiary SCIENION US, Inc. provide systems and services for the contact-free printing of biological and chemical agents for diagnostics, pharmaceutics, veterinary, plant and food analytics and research. Addressing the dynamically increasing needs for miniaturization and multiplex analyses, SCIENION offers a unique technology portfolio that has been continuously expanded over one decade. SCIENION provides flexible solutions for research and development whereas solutions for production purposes are rather customized. Systems and software are characterized by their versatility, precision and robustness. The company is renowned specialist for ultra low volume liquid handling, particularly for the handling of precious and sensitive compounds of biological or chemical origin. SCIENION’s dispensers allow for contact-free and precise drop spotting in the pico- to micro-liter range and are optimally suited for microarray based analytics – such as for tests with DNA, oligonucleotides, peptides, proteins, antibodies, glycans or for dispensing cells onto various substrates. The company operates from two sites in Germany, Dortmund and Berlin, and has a subsidiary in New Jersey, USA.
Rob Burgess, PhD
Vice President, Global Business Development